<DOC>
	<DOCNO>NCT00006143</DOCNO>
	<brief_summary>The purpose study determine effectiveness recombinant human growth hormone ( r-hGH ) growth HIV-infected child . Studies show HIV-infected child grow normal rate shorter HIV-uninfected child age . Growth hormone use many year treat child growth hormone deficiency safe effective help grow normally . The growth hormone use study , r-hGH , investigational hormone ( yet approve Food Drug Administration [ FDA ] ) make laboratory . It help HIV-positive adult gain weight improve physical performance . This study change include needle-free device drug delivery improve patient comfort acceptability . Patients longer receive growth hormone traditional needle needle-free device .</brief_summary>
	<brief_title>Growth Hormone Treatment Children With HIV-Associated Growth Failure</brief_title>
	<detailed_description>Wasting , loss lean tissue , serious consequence AIDS . Body composition finding HIV-infected child similar HIV-uninfected child classic growth hormone deficiency . Evidence suggest therapeutic administration growth hormone ( GH ) induce anabolic effect , reverse pathologic catabolism , perhaps even improve immune function . As survival adolescence beyond improves modern therapy child HIV infection , become increasingly important address problem stunt short stature population . [ AS PER AMENDMENT 09/04/01 : Recent evidence suggest needle-free delivery preferred young child age ten year . Given advantage needle-free delivery system administration growth hormone , significantly reduction risk HIV contaminate needle-stick injury care provider household member , decide use method study drug delivery study participant . ] Children assign randomly 1 follow treatment group : Group 1 : Children receive single dose r-hGH day . Group 2 : Children receive half dose r-hGH Group 1 receives , day . Group 3a : Children receive r-hGH first 24 week [ AS PER AMENDMENT 01/03/01 : 48 week ] study . After Week 24 [ AS PER AMENDMENT 01/03/01 : Week 48 ] , receive dose Group 1 . Group 3b : Children receive r-hGH first 24 week [ AS PER AMENDMENT 01/03/01 : 48 week ] study . After Week 24 [ AS PER AMENDMENT 01/03/01 : Week 48 ] , receive dose Group 2 . Subcutaneous injection administer [ AS PER AMENDMENT 09/04/01 : use needle-free device ] , daily 96 week Groups 1 2 ; 24 week [ AS PER AMENDMENT 01/03/01 : 48 week ] study , treatment-delayed control group ( Group 3 ) receive injection 72 week [ AS PER AMENDMENT 01/03/01 : 48 week ] . The first injection clinic parents/guardians train prepare administer injection . Children closely monitor toxicity , dose adjustment need . Evaluations laboratory test do clinic visit every 4 week determine growth indicator , body chemistry , CD4 cell count , HIV-1 RNA PCR , anti-hGH antibody routine hematology testing , dietary intake assessment , MRI scan . [ AS PER AMENDMENT 01/03/01 : MRI scan longer perform . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Failure Thrive</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are 4 12 year age girl , 4 13 year age boys ( consent parent/guardian require ) . Are HIVpositive . Are grow normally . Have normal intake food day . Are able walk . Have stable antiHIV therapy least 24 week study entry continue therapy entire duration study anticipate change therapy first 48 week study . ( These therapy requirement reflect change . ) Are willing able follow study requirement . Exclusion Criteria Children may eligible study : Had steady fever 101 degree F high 2 week study entry . Have serious infection require medication within 30 day prior study entry . Are fed vein . Have severe diarrhea , intestinal bleeding blockage , unable absorb food . Have cancer . Have take medication may interfere study drug radiation . Have diabetes history sugar intolerance . Have carpal tunnel syndrome ( unless surgically repair ) . Have heart kidney problem , serious swell kind . Have condition HIV infection may affect growth make difficult measure height . Have know allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Treatment Outcome</keyword>
	<keyword>serostim</keyword>
	<keyword>Developmental Disabilities</keyword>
</DOC>